Is there a future for renin inhibitors?

Bibliography

• TIGERSTEDT R, BERGMAN PG: The kidneys and the circulation. In: Ruskin R Classics in Arterial Hypertension. Nowinski WW (Ed.), Charles C Thomas Publisher, Spring-field, IL, USA (1897):274–287.
   Google Scholar
• HABER E: The role ofrenin in normal and pathological cardiovascular homeostasis. Circulation (1976) 54:849–861.
   PubMed Web of Science ®Google Scholar
• NAVAR GL, HARRISON-BERNARD LM, IMIG JD, MITCHELL KD: renal actions of ang-iotenisn II and ATI. receptors. In: Angiotensin II Receptor Antagonists. Epstein M, Brunner HR, (Eds), Hanley & Belfus, Inc., Philadelphia, PA, USA (2001) :190.
   Google Scholar
• SKEGGS LT, KAHN JR, LENTZ K, SHUMWAY NP: Prepara-tion, purification and amino acid sequence of a polypeptide renin substrate. J. Exp. Med. (1957) 106:439–453.
   PubMed Web of Science ®Google Scholar
• •Skeggs et al. recognised that the renin system could be blocked at any of 3 locations, the renin interaction with angiotensinogen, angiotensin-converting enzyme, or the ATI receptor.
   Google Scholar
• HOLLENBERG NK, FISHER NDL, PRICE DA: Pathways for angiotensin II generation in the tissues of intact humans: Evidence from comparative pharmacol-ogical interruption of the renin system. Hypertension (1998) 32:387–392.
   PubMed Web of Science ®Google Scholar
• •Evidence of non-ACE-dependent pathways for AngII generation in the intact human kidney.
   Google Scholar
• WOOD JM, STANTON JL, HOFBAUER KG: Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib. (1987) 1:169–185.
   PubMedGoogle Scholar
• HARRIS RC: Signaling and cellular effects of angiotensin II. In: Angiotensin II Receptor Antagonists. Epstein M, Brunner HR, (Eds), Hanley & Belfus, Inc., Philadelphia, PA, USA (2001):49–68.
   Google Scholar
• CHAI SY, ALLEN AM, ADAM WR, MENDELSOHN FA: Localactions of angiotensin II: quantitative in vitro autora-diographic localization of angiotensin II receptor binding and angiotensin converting enzyme in target tissues. J. Cardiovasc. Pharmacol. (1986) 8 (Suppl. 10):S35–S39.
   Google Scholar
• JAMES MN, SIELECKI A, SALITURO F, RICH DH, HOFFMANT: Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to pencillopepsin. Proc. Nat. Acad. Sci. USA (1982) 79:6137–6141.
   PubMed Web of Science ®Google Scholar
• TANG J, JAMES MNG, HSU IN, JENKINS JA, BLUNDELL TL:Structural evidence for gene duplication in the evolution of the acid proteases. Nature (1978) 271:618–621.
   PubMed Web of Science ®Google Scholar
• JAMES MN, SIELECKI AR: Stereochemical analysis ofpeptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. Biochemistry (1985) 24:3701–3713.
   PubMed Web of Science ®Google Scholar
• DZAU VJ, DEVINE D, MUDGETT-HUNTER M, KOPELMANRI, BARGER AC, HABER E: Antibodies as specific renin inhibitors: Studies with polyclonal and monoclonal antibodies and Fab fragments. Clin. Exp. Hyper-tens. (1983) 5:1207–1220.
   Web of Science ®Google Scholar
• •References 6 and 9–12 review evidence on the structure of the active site in the renin molecule.
   Google Scholar
• GROSS F, LAZAR J, ORTH H: Inhibition of the renin- angiotensinogen reaction by pepstatin. Science (1972) 175:656.
   PubMed Web of Science ®Google Scholar
• NGO TT, TUNNICLIFF G: Inhibition of enzymic reactions by transition state analogs: an approach for drug design. Gen. Pharmacol. (1981) 12:129–138.
   PubMedGoogle Scholar
• BLAINE EH, SCHORN TW, BOGER J: Statine-containing renin inhibition. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. Hypertension (1984) 6:111–118.
   Google Scholar
• KLEINERT HD, STEIN HH: Specific renin inhibitors: Concepts and prospects. In: Hypertension, Pathophysi-ology, Diagnosis and Management, (Volume 2). Laragh JH, Brenner BM (Eds.), Raven Press Ltd., New York, USA (1995):3065–3077.
   Google Scholar
• ••This is an outstanding review of the relationship betweenstructure and action in renin inhibition and an excellent overview on the evolution of the concept.
   Google Scholar
• BURTON J, CODY RJ JR., HERD JA, HABER E: Specificinhibition of renin by an ang-iotensinogen analog: Studies in sodium depletion and renin-dependent hypertension. Proc. Nat. Acad. Sci. USA (1980) 77:5476–5479.
   Google Scholar
• JEUNEMAITRE X, MENARD J, NUSSBERGER J, GUYENE TT,BRUNNER HR, CORVOL P: Plasma ang-iotensin, renin and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am. J. Hyper-tens. (1989) 2:819–827.
   PubMed Web of Science ®Google Scholar
• NEUTEL JM, LUTHER RR, BOGER RS, WEBER MA: Immediate blood pressure effects of the renin inhibitor enalkiren and the ACEinhibitor enalaprilat. Am. Heart] (1991) 122:1094–1100.
   PubMed Web of Science ®Google Scholar
• KIOWSKI W, LINDER L, KLEINBLOESEM C, VANBRUMMELEN P, BUHLER FR: Blood pressure control of the renin-angiotensin system in normotensive subjects. Circulation (1992) 85:1–8.
   PubMed Web of Science ®Google Scholar
• SIRAGY HM, LAMB NE, ROSE CE JR., PEACH MJ, CAREYRM: Intrarenal renin inhibition increases renal function by an ang-iotensin II-dependent mechanism. Am. J. Physiol. (1988) 363:F749–F754.
   Google Scholar
• VERBURG KM, KLEINERT HD, CHEKAL MA, KADAM JRC, YOUNG GA: Renal hemodynamic and excretory responses to renin inhibition induced by A-646622. J. Pharmacol. Exp. Ther. (1989) 252:449–455.
   Web of Science ®Google Scholar
• HALL JE, MIZELLE HL: Control of arterial pressure and renal function during chronic renin inhibition. J. Hypertension (1990) 8:351–359.
   PubMed Web of Science ®Google Scholar
• VERBURG KM, YOUNG GA, ROSENBERG SH, KLEINERTHD: Internal renin inhibition: renal hemodynamic and excretory actions of A-65317. Proc. Int. Soc. Hypertens. (1990) 13:66.
   Google Scholar
• CORDERO PL, FISHER NE, MOORE TJ, GLEASON R, WILLIAMS GH, HOLLENBERG NK: Renal and endocrine response to a renin inhibitor, enalkiren, in normal renin humans. Hypertension (1991) 17:510–516.
   PubMed Web of Science ®Google Scholar
• FISHER NDL, ALLAN D, KIFOR I et al.: Responses to converting enzyme and renin inhibition: role of ang-iotensin II in humans. Hypertension (1994) 23:44–51.
   PubMed Web of Science ®Google Scholar
• FISHER NDL, HOLLENBERG NK: Renal vascular responses to renin inhibition with zankiren in men. Clin. Pharmacol. Ther. (1995) 57:342–348.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG NKH, FISHER NDL: Renal circulation andblockade of the renin-angiotensin system. Is ang-iotensin-converting enzyme inhibition the last word? Hypertension (1995) 26:602–609.
   Google Scholar
• EL-AMRANI A-IK, MENARD J, GONZALES MF, MICHEL JB:Effects of blocking the angiotensin II receptor, converting enzyme and renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardio-vasc. Pharmacol. (1993) 22:231–239.
   PubMed Web of Science ®Google Scholar
• VIEIRA E, BINGGELI A, BRUE V et al.: Substitutedpiperidines - highly potent renin inhibitors due to induced fit adaptation at the active site. Biorg. Med. Chem. Lett. (1999) 9:1397–1402.
   PubMed Web of Science ®Google Scholar
• RAHUEL J, RASETTI V, MAIBAUM J et al.: Structure-baseddrug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. (2000) 7:493–04.
   PubMed Web of Science ®Google Scholar
• SIMONEAU B, LAVALLEE P, ANDERSON PC et al.:Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. Bioorg. Med. Chem. (1999) 7:489–508.
   PubMed Web of Science ®Google Scholar
• •References 30–32 from the recent literature provide evidence that several companies continue to show an interest in the development of renin inhibitors.
   Google Scholar
• PRICE DA, PORTER LE, GORDON M et al.: The Paradox of the Low-Renin State in Diabetic Nephropathy. J. Amer. Soc. Nephrol. (1999) 10:2382–2391.
   PubMed Web of Science ®Google Scholar